These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 9559843)

  • 21. Prostate specific antigen density of the transition zone for early detection of prostate cancer.
    Djavan B; Zlotta AR; Byttebier G; Shariat S; Omar M; Schulman CC; Marberger M
    J Urol; 1998 Aug; 160(2):411-8; discussion 418-9. PubMed ID: 9679889
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
    Ho PJ; Baxter RC
    Clin Endocrinol (Oxf); 1997 Feb; 46(2):145-54. PubMed ID: 9135695
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Significance of examination of prostate-specific antigen and prostate-specific antigen density in patients with prostatic hyperplasia and prostate cancer.
    Romics I; Frang D; Bodrogi I
    Int Urol Nephrol; 1997; 29(4):449-55. PubMed ID: 9406003
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Comparison of PSAD and PSAD-TZ value in prostatic hyperplasia and prostatic cancer].
    Fu Q; Yao DH; Jiang YQ
    Zhonghua Nan Ke Xue; 2002 Dec; 8(6):411-3. PubMed ID: 12593013
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prostate-specific antigen levels and density in the internal and external glands of the prostate in benign prostatic hyperplasia patients with normal or gray-zone PSA levels.
    Zuo W; Hiraoka Y
    Urol Int; 2003; 71(2):154-9. PubMed ID: 12890952
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
    Ho PJ; Baxter RC
    Clin Endocrinol (Oxf); 1997 Mar; 46(3):333-42. PubMed ID: 9156044
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lack of correlation between prostate-specific antigen density and prostatic shrinkage in response to finasteride therapy.
    Kirschenbaum A; Pacheco E; Schuval BJ; Levine AC
    World J Urol; 1996; 14(6):360-2. PubMed ID: 8986036
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PSA, PSA density, PSA density of transition zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/mL.
    Djavan B; Zlotta A; Kratzik C; Remzi M; Seitz C; Schulman CC; Marberger M
    Urology; 1999 Sep; 54(3):517-22. PubMed ID: 10475364
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prostate-specific antigen as an estimator of prostate volume in the management of patients with symptomatic benign prostatic hyperplasia.
    Mochtar CA; Kiemeney LA; van Riemsdijk MM; Barnett GS; Laguna MP; Debruyne FM; de la Rosette JJ
    Eur Urol; 2003 Dec; 44(6):695-700. PubMed ID: 14644122
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prostate specific antigen density for discriminating prostate cancer from benign prostatic hyperplasia in the gray zone of prostate-specific antigen.
    Uno H; Koide T; Kuriyama M; Ban Y; Deguchi T; Kawada Y
    Hinyokika Kiyo; 1999 Jul; 45(7):457-61. PubMed ID: 10466060
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
    Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R
    Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies.
    Haese A; Graefen M; Steuber T; Becker C; Noldus J; Erbersdobler A; Huland E; Huland H; Lilja H
    J Urol; 2003 Dec; 170(6 Pt 1):2269-73. PubMed ID: 14634394
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of prostatic disease and prostatic manipulations on the concentration of prostate-specific antigen.
    Walz PH; Schoppmann T; Büscher C; Ennen J; Schriewer H
    Eur Urol; 1992; 22(1):20-6. PubMed ID: 1385141
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relationship of prostate-specific antigen and prostate volume in patients with biopsy proven benign prostatic hyperplasia.
    Hochberg DA; Armenakas NA; Fracchia JA
    Prostate; 2000 Dec; 45(4):315-9. PubMed ID: 11102956
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [PSA/volume ratio in prostatic disease in the elderly].
    Bo M; Ventura M; Massaia M; Fabris F
    Recenti Prog Med; 2001 Oct; 92(10):594-8. PubMed ID: 11695303
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detection of prostate carcinoma using prostate specific antigen, its density, and the density of the transition zone in Japanese men with intermediate serum prostate specific antigen concentrations.
    Gohji K; Nomi M; Egawa S; Morisue K; Takenaka A; Okamoto M; Ohori M; Fujii A
    Cancer; 1997 May; 79(10):1969-76. PubMed ID: 9149025
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia.
    Ozden C; Ozdal OL; Urgancioglu G; Koyuncu H; Gokkaya S; Memis A
    Eur Urol; 2007 Jan; 51(1):199-203; discussion 204-6. PubMed ID: 16806666
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group.
    Roehrborn CG; McConnell JD; Lieber M; Kaplan S; Geller J; Malek GH; Castellanos R; Coffield S; Saltzman B; Resnick M; Cook TJ; Waldstreicher J
    Urology; 1999 Mar; 53(3):473-80. PubMed ID: 10096369
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The value of power Doppler imaging to predict the histologic components of benign prostatic hyperplasia.
    Hayami S; Ushiyama T; Kurita Y; Kageyama S; Suzuki K; Fujita K
    Prostate; 2002 Oct; 53(2):168-74. PubMed ID: 12242732
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study.
    Roehrborn CG; McConnell J; Bonilla J; Rosenblatt S; Hudson PB; Malek GH; Schellhammer PF; Bruskewitz R; Matsumoto AM; Harrison LH; Fuselier HA; Walsh P; Roy J; Andriole G; Resnick M; Waldstreicher J
    J Urol; 2000 Jan; 163(1):13-20. PubMed ID: 10604304
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.